Invesaro

Stocks Health care NTRR

OTC · Health care

Neutra Corp. (NTRR)

Neutra Corp. brought in $17.4K of revenue over the twelve months to October 31, 2023, down 82.7% from a year earlier. It posted a net loss of $473.8K. At October 31, 2023 it held $692 in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2024.

Watch NTRR in 60 seconds
Price
$0.00
0.00% on the day · September 25, 2026
52-week range $0.00 to $0.00
Market cap
$291.8K
Revenue (last 12 months)
$17.4K
-82.7% year on year
Net margin
-2,723.6%

What Neutra Corp. does

Neutra Corp. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker NTRR.

Revenue and profit by year

Revenue
FY20: $6.4K $6.4K FY20FY21: $9.7K $9.7K FY21FY22: $92K $92K FY22FY23: $68K $68K FY23
Net income
FY16: -$1.4M -$1.4M FY16FY17: -$867.9K -$867.9K FY17FY18: -$519K -$519K FY18FY19: -$2.4M -$2.4M FY19FY20: -$695.6K -$695.6K FY20FY21: -$538.9K -$538.9K FY21FY22: -$632.9K -$632.9K FY22FY23: -$561.4K -$561.4K FY23

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2023$68K-$297.7K-$561.4Kn/an/a
2022$92K-$583.6K-$632.9Kn/a-$445.8K
2021$9.7K-$478.7K-$538.9K$0.00-$608.9K
2020$6.4K-$394.2K-$695.6K$0.00n/a
2019n/a-$1.7M-$2.4M-$0.16n/a
2018n/a-$163.7K-$519K-$0.10n/a

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Neutra Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. December 12, 2024
  2. August 7, 2024
    Quarterly report 10-Q · period to April 30, 2024
  3. August 2, 2024
    Annual report 10-K · period to January 31, 2024
  4. June 17, 2024
  5. May 15, 2024
  6. April 30, 2024
  7. December 15, 2023
    Quarterly report 10-Q · period to October 31, 2023Revenue fell 94% to $1.3K versus the same quarter last year; net loss of $55K.
  8. September 14, 2023
    Quarterly report 10-Q · period to July 31, 2023Revenue fell 85% to $4.3K versus the same quarter last year; net loss of $71.8K.
  9. August 4, 2023
  10. June 22, 2023
    Quarterly report 10-Q · period to April 30, 2023Revenue fell 40% to $5.8K versus the same quarter last year; net loss of $72K.

Recent insider filings (Forms 3, 4 and 144): 1, the latest on February 4, 2014. Insider transactions on SEC

All filings on SEC EDGAR

Questions about NTRR

What does Neutra Corp. do?

Neutra Corp. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker NTRR.

Is Neutra Corp. profitable?

No. Over the twelve months to October 31, 2023 it reported a net loss of $473.8K on revenue of $17.4K.

How much revenue does Neutra Corp. make?

Over the twelve months to October 31, 2023 Neutra Corp. reported revenue of $17.4K. That is 82.7% less than a year earlier.

When did Neutra Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2024. It covers the period to April 30, 2024. Its newest filing of any kind is the deregistration from December 12, 2024.

Similar companies

Compare NTRR with

Compare NTRR with any company

Follow NTRR

Get an email when Neutra Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow NTRR: get an email when it files

Where the numbers come from

Financial figures are the values Neutra Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.